It's obvious the writer hasn't schooled themselves on the CCR5 receptor. With little knowledge of how leronlimab works, the data on a subset of patients in Covid who were given an inadequate number of doses, no complete data from the cancer trial and no complete data from LH it would be natural to look askance at any claims made. Science demands proof and in most cases the company hasn't released that proof.